Calliditas Therapeutics shares are trading higher after the company announced that it received FDA Priority Review for full approval of Nefecon.
Portfolio Pulse from Benzinga Newsdesk
Calliditas Therapeutics has received FDA Priority Review for full approval of Nefecon, leading to a rise in its share prices.
August 21, 2023 | 3:59 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Calliditas Therapeutics' shares are trading higher after the company received FDA Priority Review for Nefecon.
The FDA Priority Review for Nefecon is a significant regulatory milestone for Calliditas Therapeutics. This news is directly related to the company and is likely to have a positive impact on its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100